Forte Biosciences (FBRX)

Executive Summary

Forte Biosciences (NASDAQ: FBRX) is a clinical-stage biopharmaceutical company developing live biotherapeutic products for inflammatory skin diseases. Its lead candidate, FB-401, is a topical live bacterial therapeutic being evaluated for atopic dermatitis. The company has completed Phase 1/2 studies and is advancing FB-401 into later-stage clinical trials. Forte's approach leverages the microbiome to modulate immune responses, potentially offering a novel treatment option for patients with inflammatory skin conditions. The company is headquartered in San Diego, California, and its focus on dermatology positions it within the broader biotech sector.

Upcoming Catalysts (preview)

• Q4 2026Phase 2b topline data readout for FB-401 in atopic dermatitis40% success
• Q1 2027Initiation of Phase 3 trial for FB-40150% success
• TBDPotential partnership or licensing deal for FB-401 or platform30% success